What Neuros Medical does

Neuros Medical is a privately held medical device company that develops and commercializes neurostimulation therapies for patients with chronic post-amputation pain. Its sole commercial product, the Altius Direct Electrical Nerve Stimulation System, is an FDA-approved (PMA, August 2024) implantable neuromodulation device indicated specifically for chronic intractable phantom and residual lower limb post-amputation pain in adult amputees who have failed conventional therapies. The system consists of three components: a nerve cuff electrode placed around the affected peripheral nerve during a minimally invasive procedure, an implantable pulse generator (IPG) that delivers high-frequency electrical stimulation to block pain signal transmission to the brain, and a handheld patient controller that initiates on-demand 30-minute treatment sessions. The technology is based on patented High-Frequency Nerve Block (HFNB) bioelectric neuromodulation originally invented by researchers at Case Western Reserve University.

The company's business model is hardware sales of the Altius system to hospitals and healthcare providers for surgical implantation. Revenue is generated per implant procedure. Neuros Medical sells directly to leading hospital systems and also distributes exclusively through Veterans Healthcare Supply Solutions (VHSS) for the VA Healthcare System and Military Treatment Facilities. The company has a Patient Access Support Team that works with insurers to secure pre-approval on behalf of patients. Commercial launch began in July 2025 with the first implant at Baylor Scott & White Heart and Vascular Hospital in Dallas, TX. Headquartered in Aliso Viejo, California, Neuros Medical has raised over $194 million across multiple venture rounds (Series AA, BB, D) and growth capital facilities (Trinity Capital, 2023 and 2026), with backing from USVP, EQT Life Sciences, Amzak Health, Sectoral Asset Management, and Osage University Partners.

Name

Neuros Medical

Legal name

Neuros Medical, Inc.

Website

https://neurosmedical.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Neuros Medical is a medical device company that has developed and commercialized the FDA-approved Altius Direct Electrical Nerve Stimulation System, an implantable neuromodulation device providing patient-controlled, on-demand relief from chronic post-amputation pain in adult lower limb amputees.

Ownership category

akta.pro rank

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

akta.pro secondary industry

Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts) (HLAHAEAD)

Keywords

• Neurostimulation devices
• Peripheral nerve stimulation
• Chronic pain management
• Post-amputation pain therapy
• Implantable medical devices

Headquarters

HQ city

Willoughby

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Altius System Device Sales: The company generates revenue through the sale of its Altius Direct Electrical Nerve Stimulation System, which includes an implantable pulse generator (IPG) and nerve cuff electrode. The system is sold to healthcare providers and hospitals for implantation in patients with chronic post-amputation pain.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Neuros Medical develops and sells the Altius Direct Electrical Nerve Stimulation System, an FDA-approved implantable neuromodulation device for adult lower-limb amputees suffering chronic intractable phantom and residual post-amputation pain. The system consists of a nerve cuff electrode implanted around the affected peripheral nerve, an Implantable Pulse Generator (IPG), and a handheld patient controller that lets patients initiate 30-minute on-demand high-frequency nerve block therapy sessions to inhibit pain signals from reaching the brain. The company sells the system primarily to hospitals, pain specialists, and VA/Military Treatment Facilities that perform the implantation procedure.

Product overview

Neuros Medical offers a single unified product—the Altius Direct Electrical Nerve Stimulation System—which is an FDA-approved neuromodulation device for chronic post-amputation pain. The system consists of three integrated components: the Implantable Pulse Generator (IPG), the nerve cuff electrode (lead), and the Patient Controller. The IPG and electrode are implanted during a minimally invasive procedure, while the patient controller provides on-demand therapy initiation. This is not a platform-plus-modules architecture; it is a single medical device system with component sub-products.

Differentiator

Problem solved

Functional benefit

Brands

• Altius: Altius Direct Electrical Nerve Stimulation System - FDA-approved patient-controlled, on-demand neuromodulation device for chronic post-amputation pain.

Quantifiable outcome

• 50% pain reduction 120 minutes after initiating treatment
• +7 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Veterans Healthcare Supply Solutions (VHSS)coreChannel Partner/ Reseller/ Distributor · 5 February 2025Exclusive distribution agreement making the Altius system available at VA Healthcare and Military Treatment facilities. VHSS is a Service-Disabled Veteran Owned Small Business providing healthcare distribution to the Federal Government, headquartered in Jacksonville, FL.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Inspire Medical Systems: Inspire Medical Systems manufactures an FDA-approved implantable neurostimulation device (hypoglossal nerve stimulation) for obstructive sleep apnea — a structurally similar playbook: single indication, FDA approval as competitive moat, enterprise field sales to specialists, and reliance on payor coverage. Directly comparable business model to Neuros Medical's Altius.
• Nevro Corp: Nevro manufactures the Senza spinal cord stimulation (SCS) system for chronic pain of the trunk and limbs. Closely comparable as a pure-play implantable neuromodulation company focused on chronic pain, with similar payor coverage dynamics and enterprise hospital sales motion.
• Axonics Modulation Technologies: Axonics develops implantable neuromodulation devices (sacral and now bulkamid) for bladder/bowel dysfunction. Similar small-cap medical device profile, FDA-approved implantable platform, and growth-stage commercial trajectory targeting specialty physician call points.

Broad incumbents

• Boston Scientific (Neuromodulation): Boston Scientific operates one of the largest neuromodulation franchises (Precision SCS, WaveWriter, Vercise DBS) and is also an existing Neuros Medical investor. As a broad incumbent, it offers overlapping technology capabilities and has far deeper commercial reach — a potential acquirer or competitor to Neuros.
• Abbott (Neuromodulation / St. Jude): Abbott acquired St. Jude Medical and operates neuromodulation franchises including Proclaim SCS, Proclaim DRG, and Infinity DBS. A broad incumbent with established payer relationships and surgeon training infrastructure that could expand into peripheral nerve indications.
• Medtronic (Neuromodulation): Medtronic is the global leader in implantable neurostimulation with Vanta SCS, Intellis with DTM, Percept PC DBS, and intrathecal drug pumps. As the largest incumbent neuromodulator, it sets the competitive benchmark and payor framework Neuros must navigate.

Emerging players

• Saluda Medical: Saluda Medical is developing the Evoke ECAP-based closed-loop SCS system for chronic pain. Comparable as an emerging neuromodulation company with novel mechanism of action competing in chronic pain with a focus on objective dosing evidence — paralleling Neuros's evidence-driven positioning.
• Nalu Medical: Nalu Medical develops a miniaturized peripheral nerve stimulation (PNS) system for chronic pain. Highly relevant as a direct competitor in peripheral nerve stimulation for chronic pain — overlapping therapeutic category with Altius, though using a different stimulation modality and energy source.
• SPR Therapeutics: SPR Therapeutics commercializes the Sprint PNS system, a percutaneous peripheral nerve stimulator for chronic and acute pain. Comparable as an emerging peripheral nerve stimulation company addressing chronic pain with a less-invasive approach, competing for similar physician call points and payor pathways.
• Mainstay Medical: Mainstay Medical commercializes the ReActiv8 restorative neurostimulation system for chronic mechanical low back pain. Comparable as a small-cap, single-product implantable neuromodulation company targeting a specific chronic pain indication with a specialized field sales motion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/neuros-medical-inc.

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds15 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuros Medical